Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.
Jayakanth Kankanala,Carlos Ribeiro,Evgeny Kiselev,Azhar Ravji,Jessica Williams,Jiashu Xie,Hideki Aihara,Yves Pommier,Zhengqiang Wang +8 more
TL;DR: Two novel subtypes of the deazaflavin TDP2 inhibitor core are reported, generating novel analogues with considerably improved biochemical potency and/or permeability and suggesting that these analogues could serve as effective cellular probes.
Patent
Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (TDP1)
TL;DR: In this paper, a method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound, was proposed.
Journal ArticleDOI
Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway
Jessica Marinello,Andrea Arleo,Marco Russo,Maria Delcuratolo,Francesca D. Ciccarelli,Yves Pommier,Giovanni Capranico +6 more
TL;DR: In this article , the authors used molecular, genetic and bioinformatic approaches to determine the mechanism of micronuclei formation induced by two TOP1 poisons in different human cancer cells, including SCLC cell lines.
Journal ArticleDOI
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Matthew Ingham,Jacob B. Allred,Katherine Gano,Suzanne George,Steven Attia,Melissa Amber Burgess,Mahesh Seetharam,Sosipatros A. Boikos,Nam Bui,James L. Chen,Julia Close,Gregory M. Cote,Premal H. Thaker,S. Percy Ivy,Biswajit Das,Geoffrey I. Shapiro,Bose Kochupurakkal,Jane B. Trepel,Yves Pommier,Gary K. Schwartz +19 more
TL;DR: This data indicates that a second line therapy is needed for the characterization of smooth muscle sarcoma-like granuloma-like lesions in women with previously undiagnosed central giant cell carcinoma.
Journal ArticleDOI
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
TL;DR: The ZW-1288 derivative represents a promising direction for the development of deazaflavins as therapeutic agents and exhibits potent inhibitory activity at low nanomolar concentrations against recombinant and cellular human TDP2 with profile similar to that of the parent analog SV-5-153.